Trial reportNature communications2018
Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer.
Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph
Trial report in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04770376 (Prospective Pilot Study for the Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1), which is not on this map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
10.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Pilot Study for the Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 (ANG1) and Endothelial Internal Tunica Cell Kinase 2 (TiE2) in Patients With Ovarian Cancer Treated With Chemotherapy Associated to bevAcizumab
Who cites it
42 citing papers in PubMed, 74 citations in OpenAlex.
- Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.British journal of cancer · 2024Trial
- Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.British journal of clinical pharmacology · 2019Trial
- Aflibercept and Faricimab Equipotently Restore Endothelial Barrier Function.Investigative ophthalmology & visual science · 2026Article
- Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.EClinicalMedicine · 2026Article
- Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers.Clinical and translational medicine · 2026Review
- Predicting Survival in Bevacizumab-Treated Colorectal Cancer: Personalized Mathematical Models Based on Clinical and Angiogenic Biomarkers.International journal of molecular sciences · 2025Article
- Deep learning models for deriving optimised measures of fat and muscle mass from MRI.Scientific reports · 2025Article
- Measuring repeatability of dynamic contrast-enhanced MRI biomarkers improves evaluation of biological response to radiotherapy in lung cancer.European radiology · 2025Article
- Global research landscape of antiangiogenic therapy for colorectal cancer: a bibliometric analysis of mechanistic insights and clinical advancements.Frontiers in oncology · 2025Review
- Oxygen-Enhanced MRI Detects Incidence, Onset, and Heterogeneity of Radiation-Induced Hypoxia Modification in HPV-Associated Oropharyngeal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Phase II study of ramucirumab and docetaxel for previously platinum-treated patients with non-small cell lung cancer and malignant pleural effusion (PLEURAM study).Translational lung cancer research · 2024Article
- The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors.BMC cancer · 2024Article
- Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer.Journal for immunotherapy of cancer · 2024Article
- Article
- Article
- Review
- Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer.Oncology research · 2023Article
- Extracellular vesicles rich in HAX1 promote angiogenesis by modulating ITGB6 translation.Journal of extracellular vesicles · 2022Article
- The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.British journal of cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 8 institutions in 3 countries.
Gordon C JaysonThe Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, M20 4BX, UK. Gordon.Jayson@manchester.ac.uk.
Cong ZhouDivision of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester, M20 4GJ, UK.
Alison BackenClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute & Manchester Centre for Cancer Biomarker Sciences, Manchester, M20 4BX, UK.
Laura HorsleyThe Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, M20 4BX, UK.
Kalena Marti-MartiThe Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, M20 4BX, UK.
Danielle ShawClatterbridge Cancer Centre, Liverpool, CH63 4JY, UK.
Nerissa MescalladoThe Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, M20 4BX, UK.
Andrew ClampManchester Academic Health Science Centre, Trials Co-ordination Unit, The Christie NHS Foundation Trust, Withington Hall Block C, Wilmslow Road, Manchester, M20 4BX, UK.
Mark P SaundersManchester Academic Health Science Centre, Trials Co-ordination Unit, The Christie NHS Foundation Trust, Withington Hall Block C, Wilmslow Road, Manchester, M20 4BX, UK.
Juan W ValleThe Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, M20 4BX, UK.
Saifee MullamithaManchester Academic Health Science Centre, Trials Co-ordination Unit, The Christie NHS Foundation Trust, Withington Hall Block C, Wilmslow Road, Manchester, M20 4BX, UK.
Mike BraunManchester Academic Health Science Centre, Trials Co-ordination Unit, The Christie NHS Foundation Trust, Withington Hall Block C, Wilmslow Road, Manchester, M20 4BX, UK.
Jurjees HasanManchester Academic Health Science Centre, Trials Co-ordination Unit, The Christie NHS Foundation Trust, Withington Hall Block C, Wilmslow Road, Manchester, M20 4BX, UK.
Delyth McEnteeManchester Academic Health Science Centre, Trials Co-ordination Unit, The Christie NHS Foundation Trust, Withington Hall Block C, Wilmslow Road, Manchester, M20 4BX, UK.
Kathryn SimpsonClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute & Manchester Centre for Cancer Biomarker Sciences, Manchester, M20 4BX, UK.
Ross A LittleImaging Sciences, University of Manchester, Manchester, M13 9PT, UK.
Yvonne WatsonImaging Sciences, University of Manchester, Manchester, M13 9PT, UK.
Susan CheungImaging Sciences, University of Manchester, Manchester, M13 9PT, UK.
Caleb RobertsImaging Sciences, University of Manchester, Manchester, M13 9PT, UK.
Linda AshcroftManchester Academic Health Science Centre, Trials Co-ordination Unit, The Christie NHS Foundation Trust, Withington Hall Block C, Wilmslow Road, Manchester, M20 4BX, UK.
Prakash ManoharanThe Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, M20 4BX, UK.
Stefan J SchererNovartis Pharmaceuticals Corporation, One Health Plaza, 337, East Hanover, NJ, 07936-1080, USA.
Olivia Del PuertoDel Puerto Limited, 23 Porters Wood; Saint Albans, Hertfordshire, AL3 6PQ, UK.
Alan JacksonImaging Sciences, University of Manchester, Manchester, M13 9PT, UK.
James P B O'ConnorDivision of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester, M20 4GJ, UK.
Geoff J M ParkerImaging Sciences, University of Manchester, Manchester, M13 9PT, UK.
Caroline DiveClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute & Manchester Centre for Cancer Biomarker Sciences, Manchester, M20 4BX, UK.
University of Manchester · GBThe Christie NHS Foundation Trust · GBManchester Academic Health Science Centre · GBCancer Research UK Manchester Institute · GBClatterbridge Cancer Centre NHS Foundation Trust · GBDynavax Technologies (Germany) · DETris Pharma (United States) · USWest Hertfordshire Hospitals NHS Trust · GB
Funding
Cancer Research UK 15267Cancer Research UK 16465Cancer Research UK 18097Cancer Research UK 19278Cancer Research UK 20465Cancer Research UK 22746
Abstract
Oncological use of anti-angiogenic VEGF inhibitors has been limited by the lack of informative biomarkers. Previously we reported circulating Tie2 as a vascular response biomarker for bevacizumab-treated ovarian cancer patients. Using advanced MRI and circulating biomarkers we have extended these findings in metastatic colorectal cancer (n = 70). Bevacizumab (10 mg/kg) was administered to elicit a biomarker response, followed by FOLFOX6-bevacizumab until disease progression. Bevacizumab induced a correlation between Tie2 and the tumor vascular imaging biomarker, K
Indexed as
AdultAgedAngiogenesis InhibitorsAngiopoietin-2BevacizumabBiomarkers, TumorColorectal NeoplasmsDisease-Free SurvivalDisease ProgressionFemaleHumansKaplan-Meier EstimateMaleMiddle AgedModels, BiologicalNeovascularization, PathologicAngiogenesis InhibitorsAngiopoietin-2BevacizumabBiomarkers, TumorReceptor, TIE-2TEK protein, humanVascular Endothelial Growth Factor A
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT04770376ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.